Biomarkers of Alzheimer's disease

2007 Abdi, 2006, Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders, J. Alzheimers Dis., 9, 293, 10.3233/JAD-2006-9309 Abraham, 1988, Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease, Cell, 52, 487, 10.1016/0092-8674(88)90462-X Agdeppa, 2001, In vivo and in vitro labeling of plaques and tangles in the brain of an Alzheimer's disease patient: a case study, J. Nucl. Med., 42, 65P Akiyama, 2000, Inflammation and Alzheimer's disease, Neurobiol. Aging, 21, 383, 10.1016/S0197-4580(00)00124-X Alsop, 2000, Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging, Ann. Neurol., 47, 93, 10.1002/1531-8249(200001)47:1<93::AID-ANA15>3.0.CO;2-8 Andreasen, 1998, Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study, J. Neurol. Neurosurg. Psych., 64, 298, 10.1136/jnnp.64.3.298 Andreasen, 1999, Cerebrospinal fluid β-amyloid(1-42) in Alzheimer's disease: differences between early- and late-onset Alzheimer's disease and stability during the course of disease, Arch. Neurol., 56, 673, 10.1001/archneur.56.6.673 Andreasen, 1999, Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample, Neurology, 53, 1488, 10.1212/WNL.53.7.1488 Andreasen, 2001, Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer's disease in clinical practice, Arch. Neurol., 58, 373, 10.1001/archneur.58.3.373 Andreasen, 2003, Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment, Acta Neurol. Scand. Suppl., 179, 47, 10.1034/j.1600-0404.107.s179.9.x Angelis, 1998, Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease, Neurosci. Lett., 244, 106, 10.1016/S0304-3940(98)00136-0 Arai, 1995, Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease, Ann. Neurol., 38, 649, 10.1002/ana.410380414 Arai, 1997, Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer's disease, J. Am. Geriatr. Soc., 45, 1228, 10.1111/j.1532-5415.1997.tb03775.x Arai, 1998, No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia, Neurosci. Lett., 256, 174, 10.1016/S0304-3940(98)00781-2 Archer, 2006, Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study, Ann. Neurol., 60, 145, 10.1002/ana.20889 Arnaiz, 2001, Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment, Neuroreport, 12, 851, 10.1097/00001756-200103260-00045 Arriagada, 1992, Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease, Neurology, 42, 631, 10.1212/WNL.42.3.631 Bacskai, 2007, Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report, Arch. Neurol., 64, 431, 10.1001/archneur.64.3.431 Ballatore, 2007, Tau-mediated neurodegeneration in Alzheimer's disease and related disorders, Nat. Rev. Neurosci., 8, 663, 10.1038/nrn2194 Barger, 1997, Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E, Nature, 388, 878, 10.1038/42257 Barnes, 2006, Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration, Arch. Neurol., 63, 1434, 10.1001/archneur.63.10.1434 Barnes, 2007, Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD, Neurobiol. Aging, 28, 20, 10.1016/j.neurobiolaging.2005.11.012 Barrio, 1999, PET imaging of tangles and plaques in Alzheimer disease with a highly hydrophobic probe, J. Labelled Compd. Radiopharm., 42, S194 Becker, 1996, Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer's disease, Neurology, 46, 692, 10.1212/WNL.46.3.692 Bierer, 1995, Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease, Arch. Neurol., 52, 81, 10.1001/archneur.1995.00540250089017 Blennow, 2003, CSF markers for incipient Alzheimer's disease, Lancet Neurol., 2, 605, 10.1016/S1474-4422(03)00530-1 Blennow, 1995, Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?, Mol. Chem. Neuropathol., 26, 231, 10.1007/BF02815140 Blum-Degen, 1995, Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients, Neurosci. Lett., 202, 17, 10.1016/0304-3940(95)12192-7 Bohnstedt, 2003, Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography-tandem mass spectrometry, J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 796, 11, 10.1016/S1570-0232(03)00600-7 Borroni, 2006, Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD, Neurobiol. Aging, 27, 24, 10.1016/j.neurobiolaging.2004.12.010 Bosscher, 2001, MRI of the temporal lobe Bouras, 1993, Neurofibrillary tangle densities in the hippocampal formation in a non-demented population define subgroups of patients with differential early pathologic changes, Neurosci. Lett., 153, 131, 10.1016/0304-3940(93)90305-5 Bozzao, 2001, Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load, AJNR Am. J. Neuroradiol., 22, 1030 Braak, 1991, Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol., 82, 239, 10.1007/BF00308809 Bradley, 2002, Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease, Brain, 125, 1772, 10.1093/brain/awf185 Bresjanac, 2003, Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene) malononitrile labels prion plaques in vitro, J. Neurosci., 23, 8029, 10.1523/JNEUROSCI.23-22-08029.2003 Brugge, 1992, Serological alpha 1-antichymotrypsin in Down's syndrome and Alzheimer's disease, Ann. Neurol., 32, 193, 10.1002/ana.410320211 Buerger, 2002, Differential diagnosis of Alzheimer's disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231, Arch. Neurol., 59, 1267, 10.1001/archneur.59.8.1267 Burger nee Buch, 1999, Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old patients with Alzheimer's disease compared with controls, Neurosci. Lett., 277, 21, 10.1016/S0304-3940(99)00845-9 Burns, 1989, The investigation of Alzheimer's disease with single photon emission tomography, J. Neurol. Neurosurg. Psychiatry, 52, 248, 10.1136/jnnp.52.2.248 Cagnin, 2001, In-vivo measurement of activated microglia in dementia, Lancet, 358, 461, 10.1016/S0140-6736(01)05625-2 Carlson, 2008, Trajectories of brain loss in aging and the development of cognitive impairment, Neurology, 70, 828, 10.1212/01.wnl.0000280577.43413.d9 Carrette, 2003, A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease, Proteomics, 3, 1486, 10.1002/pmic.200300470 Castano, 2006, Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects, Neurol. Res., 28, 155, 10.1179/016164106X98035 Celone, 2006, Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis, J. Neurosci., 26, 10222, 10.1523/JNEUROSCI.2250-06.2006 Chetelat, 2005, Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study, NeuroImage, 1 Choe, 2002, Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease, Electrophoresis, 23, 2247, 10.1002/1522-2683(200207)23:14<2247::AID-ELPS2247>3.0.CO;2-M Chong, 1990, Detection of amyloid beta protein precursor immunoreactivity in normal and Alzheimer's disease cerebrospinal fluid, Life Sci., 47, 1163, 10.1016/0024-3205(90)90177-S Clark, 2003, Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch, Neurol., 60, 1696 Combs, 1999, Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins, J. Neurosci., 19, 928, 10.1523/JNEUROSCI.19-03-00928.1999 Csernansky, 2002, Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type, Alzheimer Dis. Assoc. Disord., 16, 144, 10.1097/00002093-200207000-00003 Davidsson, 2002, Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients, NeuroReport, 13, 611, 10.1097/00001756-200204160-00015 DeKosky, 2003, Plasma and cerebrospinal fluid alpha-1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment, Ann. Neurol., 53, 81, 10.1002/ana.10414 de Leon, 2007, Longitudinal CSF isoprostane and MRI atrophy in the progression to AD, J. Neurol. Sci., 14 de Leon, 2001, Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-d-glucose/poitron-emission tomography (FDG/PET), Proc. Natl. Acad. Sci. U. S. A., 98, 10966, 10.1073/pnas.191044198 de Leon, 2006, Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment, Neurobiol. Aging, 27, 394, 10.1016/j.neurobiolaging.2005.07.003 De Leon, 1997, Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease, Neurobiol. Aging, 18, 1, 10.1016/S0197-4580(96)00213-8 DeMattos, 2002, Plaque-associated disruption of CSF and plasma amyloid-β (Aβ) equilibrium in a mouse model of Alzheimer's disease, J. Neurochem., 81, 229, 10.1046/j.1471-4159.2002.00889.x deToledo-Morrell, 2004, MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD, Neurobiol. Aging, 25, 1197, 10.1016/j.neurobiolaging.2003.12.007 Dickerson, 2004, Medial temporal lobe function and structure in mild cognitive impairment, Ann. Neurol., 56, 27, 10.1002/ana.20163 Dickerson, 2005, Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD, Neurology, 65, 404, 10.1212/01.wnl.0000171450.97464.49 Dickerson, 2008, Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies, Neuropsychologia, 46, 1624, 10.1016/j.neuropsychologia.2007.11.030 Drzezga, 2005, Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET, J. Nucl. Med., 46, 1625 Drzezga, 2008, Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease, Neuroimage, 39, 619, 10.1016/j.neuroimage.2007.09.020 Du, 2006, Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI, Neurology, 67, 1215, 10.1212/01.wnl.0000238163.71349.78 Engelborghs, 1999, Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type, Neurochem. Int., 34, 523, 10.1016/S0197-0186(99)00031-5 Engelborghs, 2008, Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia, Neurobiol. Aging, 29, 1143, 10.1016/j.neurobiolaging.2007.02.016 Engelhart, 2004, Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study, Arch. Neurol., 61, 668, 10.1001/archneur.61.5.668 Engler, 2006, Two-year follow-up of amyloid deposition in patients with Alzheimer's disease, Brain, 129, 2856, 10.1093/brain/awl178 Ertekin-Taner, 2008, Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families, Neurology, 70, 596, 10.1212/01.wnl.0000278386.00035.21 Evin, 2002, Biogenesis and metabolism of Alzheimer's disease Abeta amyloid peptides, Peptides, 23, 1285, 10.1016/S0196-9781(02)00063-3 Fagan, 2006, Inverse relation between in vivo amyloid imaging load and CSF Aβ42 in humans, Ann. Neurol., 59, 512, 10.1002/ana.20730 Fagan, 2007, Cerebrospinal fluid tau/Aβ42 ratio as a prediction of cognitive decline in nondemented older adults, Arch. Neurol., 64, 343, 10.1001/archneur.64.3.noc60123 Feillet-Coudray, 1999, Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease, Free Radic. Biol. Med., 27, 463, 10.1016/S0891-5849(99)00096-9 Finehout, 2006, Proteomic analysis of cerebrospinal fluid changes related to postmortem interval, Clin. Chem., 52, 1906, 10.1373/clinchem.2006.070508 Finehout, 2006, Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease, Ann. Neurol., 61, 120, 10.1002/ana.21038 Flirski, 2005, Biochemical markers and risk factors of Alzheimer's disease, Curr. Alzheimer Res., 2, 47, 10.2174/1567205052772704 Forsberg, 2007, PET imaging of amyloid deposition in patients with mild cognitive impairment, Neurobiol. Aging, 29, 1456, 10.1016/j.neurobiolaging.2007.03.029 Fotenos, 2005, Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD, Neurology, 64, 1032, 10.1212/01.WNL.0000154530.72969.11 Freeman, 2007, Plasma Abeta levels do not reflect brain Abeta levels, J. Neuropathol. Exp. Neurol., 66, 264, 10.1097/NEN.0b013e31803d3ae4 Frisoni, 2001, Structural imaging in the clinical diagnosis of Alzheimer's disease: problems and tools, J. Neurol. Neurosurg. Psychiatry, 70, 711, 10.1136/jnnp.70.6.711 Fukumoto, 2003, Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels, Arch. Neurol., 60, 958, 10.1001/archneur.60.7.958 Fukuyama, 2000, Age-dependent changes in the levels of Aβ40 and Aβ42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Aβ42 to Aβ40 level in cerebrospinal fluid from Alzheimer's disease patients, Eur. Neurol., 43, 155, 10.1159/000008156 Furby, 1991, Are alpha-1-antichymotrypsin and inter-alpha-trypsin inhibitor peripheral markers of Alzheimer's disease?, J. Neurol. Neurosurg. Psychiatry, 54, 469, 10.1136/jnnp.54.5.469 Galasko, 1998, High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer's disease and relation to apolipoprotein E genotype, Arch. Neurol., 55, 937, 10.1001/archneur.55.7.937 Gejyo, 1985, A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin, Biochem. Biophys. Res. Commun., 129, 701, 10.1016/0006-291X(85)91948-5 German, 2007, Serum biomarkers for Alzheimer's disease: proteomic discovery, Biomed. Pharmacother., 61, 383, 10.1016/j.biopha.2007.05.009 Ghiso, 1989, Alzheimer's disease amyloid precursor protein is present in senile plaques and cerebrospinal fluid: immunohistochemical and biochemical characterization, Biochem. Biophys. Res. Commun., 163, 430, 10.1016/0006-291X(89)92154-2 Golombowski, 1997, Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease, Neurosci. Lett., 225, 213, 10.1016/S0304-3940(97)00228-0 Gomez-Isla, 1996, Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease, J. Neurosci., 16, 4491, 10.1523/JNEUROSCI.16-14-04491.1996 Gonzalez, 1995, Functional MR in the evaluation of dementia: correlation of abnormal dynamic cerebral blood volume measurements with changes in cerebral metabolism on positron emission tomography with fludeoxyglucose F 18, AJNR Am. J. Neuroradiol., 16, 1763 Gorevic, 1985, Beta-2 microglobulin is an amyloidogenic protein in man, J. Clin. Invest., 76, 2425, 10.1172/JCI112257 Grady, 2001, Altered brain functional connectivity and impaired short-term memory in Alzheimer's disease, Brain, 124, 739, 10.1093/brain/124.4.739 Green, 1999, Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease, Neurosci. Lett., 259, 133, 10.1016/S0304-3940(98)00904-5 Groom, 1995, PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease, J. Nucl. Med., 36, 2207 Grossman, 2005, Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease, Ann. Neurol., 57, 721, 10.1002/ana.20477 Hamalainen, 2007, Increased fMRI responses during encoding in mild cognitive impairment, Neurobiol. Aging, 28, 1889, 10.1016/j.neurobiolaging.2006.08.008 Hampel, 1997, Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease, Neurosci. Lett., 228, 143, 10.1016/S0304-3940(97)00379-0 Hampel, 1999, Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease, Brain Res., 823, 104, 10.1016/S0006-8993(99)01146-4 Hampel, 2001, Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231, Ann. Neurol., 49, 545, 10.1002/ana.111 Hampel, 2004, Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment, Mol. Psychiatry, 9, 705, 10.1038/sj.mp.4001473 Hampel, 2004, Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study, Arch. Gen. Psychiatry, 61, 95, 10.1001/archpsyc.61.1.95 Hansson, 2006, Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol., 5, 228, 10.1016/S1474-4422(06)70355-6 Hansson, 2007, Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment, Dement. Geriatr. Cogn. Disord., 23, 316, 10.1159/000100926 Hansson, 2008, Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment, Neurobiol. Aging (Electronic publication ahead of print, PMID: 18954920) Harigaya, 1995, Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease, Intern Med., 34, 481, 10.2169/internalmedicine.34.481 Haroutunian, 1999, Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease, Arch. Neurol., 56, 713, 10.1001/archneur.56.6.713 Harris, 1998, Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine, AJNR Am. J. Neuroradiol., 19, 1727 Hasegawa, 2000, Increased soluble tumor necrosis factor receptor levels in the serum of elderly people, Gerontology, 46, 185, 10.1159/000022157 Henriksson, 1991, Analysis and quantitation of the beta-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay, J. Neurochem., 56, 1037, 10.1111/j.1471-4159.1991.tb02026.x Herukka, 2005, CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment, Neurology, 64, 1294, 10.1212/01.WNL.0000156914.16988.56 Herukka, 2007, CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI, Neurobiol. Aging, 28, 507, 10.1016/j.neurobiolaging.2006.02.001 Hinds, 1994, Relationship between serum alpha 1-antichymotrypsin and Alzheimer's disease, Neurobiol. Aging, 15, 21, 10.1016/0197-4580(94)90141-4 Hirao, 2005, The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT, Neuroimage, 28, 1014, 10.1016/j.neuroimage.2005.06.066 Hock, 1995, Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease—correlation with degree of cognitive impairment, Ann. Neurol., 37, 414, 10.1002/ana.410370325 Hoffman, 2000, FDG PET imaging in patients with pathologically verified dementia, J. Nucl. Med., 41, 1920 Holmberg, 2003, Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy, Mov. Disord., 18, 186, 10.1002/mds.10321 Holmes, 2008, Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial, Lancet, 372, 216, 10.1016/S0140-6736(08)61075-2 Hu, 2005, Comparative proteomic analysis of intra-and interindividual variation in human cerebrospinal fluid, Mol. Cell. Proteom., 4, 2000, 10.1074/mcp.M500207-MCP200 Hu, 2007, Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease, Proteomics- Clin. Appl., 1, 1373, 10.1002/prca.200600999 Huang, 2002, Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment, BMC Neurol., 2, 9, 10.1186/1471-2377-2-9 Huang, 2003, Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment, Neuroimage, 19, 1137, 10.1016/S1053-8119(03)00168-X Huang, 2007, Imaging markers of mild cognitive impairment: multivariate analysis of CBF SPECT, Neurobiol. Aging, 28, 1062, 10.1016/j.neurobiolaging.2006.05.017 Hulette, 1998, Neuropathological and neuropsychological changes in “normal” aging: evidence for preclinical Alzheimer disease in cognitively normal individuals, J. Neuropathol. Exp. Neurol., 57, 1168, 10.1097/00005072-199812000-00009 Hulstaert, 1999, Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF, Neurology, 52, 1555, 10.1212/WNL.52.8.1555 Hunter, 1989, The pattern of function-related regional cerebral blood flow investigated by single photon emission tomography with 99mTc-HMPAO in patients with presenile Alzheimer's disease and Korsakoff's psychosis, Psychol. Med., 19, 847, 10.1017/S0033291700005560 Hye, 2006, Proteome-based plasma biomarkers for Alzheimer's disease, Brain, 129, 3042, 10.1093/brain/awl279 Ida, 1996, Analysis of heterogeneous βA4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay, J. Biol. Chem., 271, 22908, 10.1074/jbc.271.37.22908 Irizarry, 2007, Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease, Neurodegener Dis., 4, 403, 10.1159/000107699 Itoh, 2001, Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease, Ann. Neurol., 50, 150, 10.1002/ana.1054 Jack, 2008, 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment, Brain, 131, 665, 10.1093/brain/awm336 Jagust, 2001, SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical–pathologic study, Neurology, 56, 950, 10.1212/WNL.56.7.950 Janus, 2000, A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature, 408, 979, 10.1038/35050110 Jensen, 1995, Increased cerebrospinal fluid tau in patients with Alzheimer's disease, Neurosci. Lett., 186, 189, 10.1016/0304-3940(95)11297-A Jensen, 1999, Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression, Ann. Neurol., 45, 504, 10.1002/1531-8249(199904)45:4<504::AID-ANA12>3.0.CO;2-9 Jia, 2005, Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia, Neurosci. Lett., 383, 12, 10.1016/j.neulet.2005.03.051 Jobst, 1992, Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease, J. Neurol. Neurosurg. Psychiatry, 55, 190, 10.1136/jnnp.55.3.190 Johnson, 2005, Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience, Radiology, 234, 851, 10.1148/radiol.2343040197 Johnson, 2006, Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment, Neurobiol. Aging, 27, 1604, 10.1016/j.neurobiolaging.2005.09.017 Johnson, 2007, Imaging of amyloid burden and distribution in cerebral amyloid angiopathy, Ann. Neurol., 62, 229, 10.1002/ana.21164 Kahle, 2000, Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF, Neurology, 54, 1498, 10.1212/WNL.54.7.1498 Kalman, 1997, Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease, Acta Neurol. Scand., 96, 236, 10.1111/j.1600-0404.1997.tb00275.x Kanai, 1998, Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease: a study in Japan, Ann. Neurol., 44, 10.1002/ana.410440108 Kanemaru, 2000, Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies, Neurology, 54, 1875, 10.1212/WNL.54.9.1875 Kapaki, 2001, Highly increased CSF tau protein and decreased beta-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer's disease?, J. Neurol. Neurosurg. Psychiatry, 71, 401, 10.1136/jnnp.71.3.401 Kapaki, 2003, CSF tau protein and beta-amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population, Eur. J. Neurol., 10, 119, 10.1046/j.1468-1331.2003.00562.x Kato, 2001, Dissociation of regional activation in mild AD during visual encoding: a functional MRI study, Neurology, 57, 812, 10.1212/WNL.57.5.812 Kemppainen, 2006, Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease, Neurology, 67, 1575, 10.1212/01.wnl.0000240117.55680.0a Kemppainen, 2007, PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment, Neurology, 68, 1603, 10.1212/01.wnl.0000260969.94695.56 Killiany, 2000, Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease, Ann. Neurol., 47, 430, 10.1002/1531-8249(200004)47:4<430::AID-ANA5>3.0.CO;2-I Kircher, 2007, Hippocampal activation in patients with mild cognitive impairment is necessary for successful memory encoding, J. Neurol. Neurosurg. Psychiatry, 78, 812, 10.1136/jnnp.2006.104877 Kitaguchi, 1990, Determination of amyloid beta protein precursors harboring active form of proteinase inhibitor domains in cerebrospinal fluid of Alzheimer's disease patients by trypsin-antibody sandwich ELISA, Biochem. Biophys. Res. Commun., 166, 1453, 10.1016/0006-291X(90)91030-V Klunk, 2004, Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B, Ann. Neurol., 55, 306, 10.1002/ana.20009 Klunk, 2007, Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees, J. Neurosci., 27, 6174, 10.1523/JNEUROSCI.0730-07.2007 Kogure, 2000, Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT, J. Nucl. Med., 41, 1155 Kohnken, 2000, Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients, Neurosci. Lett., 287, 187, 10.1016/S0304-3940(00)01178-2 Kordower, 2001, Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment, Ann. Neurol., 49, 202, 10.1002/1531-8249(20010201)49:2<202::AID-ANA40>3.0.CO;2-3 Kosaka, 1997, The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at Abeta42(43), Neurology, 48, 741, 10.1212/WNL.48.3.741 Kudo, 2007, 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients, J. Nucl. Med., 48, 553, 10.2967/jnumed.106.037556 Kurz, 1998, Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease, Alzheimer Dis. Assoc. Disord., 12, 372, 10.1097/00002093-199812000-00020 Lannfelt, 1995, Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation, Neurosci. Lett., 199, 203, 10.1016/0304-3940(95)12059-D Lanzrein, 1998, Alzheimer Dis. Assoc. Disord., 12, 215, 10.1097/00002093-199809000-00016 Laterza, 2006, Identification of novel brain biomarkers, Clin. Chem., 52, 1713, 10.1373/clinchem.2006.070912 Lee, 2008, The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients, Clin. Chem., 54, 1617, 10.1373/clinchem.2008.104497 Lewczuk, 2004, Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau, Neurobiol. Aging, 25, 273, 10.1016/S0197-4580(03)00086-1 Lewis, 2001, Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP, Science, 293, 1487, 10.1126/science.1058189 Leys, 1989, [Alzheimer's disease: study by single photon emission tomography (Hm PAO Tc99m)], Rev. Neurol. (Paris), 145, 443 Li, 2007, CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: a follow-up study, Neurology, 69, 631, 10.1212/01.wnl.0000267428.62582.aa Licastro, 2000, Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?, J. Neuroimmunol., 103, 97, 10.1016/S0165-5728(99)00226-X Lieberman, 1995, Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia, Neurobiol. Aging, 16, 747, 10.1016/0197-4580(95)00056-K Lopez, 2005, High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures, Clin. Chem., 51, 1946, 10.1373/clinchem.2005.053090 Lopez, 2008, Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study, Neurology, 70, 1664, 10.1212/01.wnl.0000306696.82017.66 Lopresti, 2005, Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis, J. Nucl. Med., 46, 1959 Machulda, 2003, Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients, Neurology, 61, 500, 10.1212/01.WNL.0000079052.01016.78 Maddalena, 2003, Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42, Arch. Neurol., 60, 1202, 10.1001/archneur.60.9.1202 Maeda, 2007, Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography, J. Neurosci., 27, 10957, 10.1523/JNEUROSCI.0673-07.2007 Maes, 1999, Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer's disease, J. Psychiatr. Res., 33, 397, 10.1016/S0022-3956(99)00016-3 Mandelkow, 1998, Tau in Alzheimer's disease, Trends Cell Biol., 8, 425, 10.1016/S0962-8924(98)01368-3 Markesbery, 2006, Neuropathologic substrate of Mild Cognitive Impairment, Arch. Neurol., 63, 38, 10.1001/archneur.63.1.38 Martinez, 2000, Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease. Relationship with IL-6 concentrations, Brain Res., 869, 216, 10.1016/S0006-8993(00)02363-5 Marz, 1997, Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients, Neurosci. Lett., 239, 29, 10.1016/S0304-3940(97)00886-0 Mathis, 2003, Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents, J. Med. Chem., 46, 2740, 10.1021/jm030026b Matsubara, 1990, Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia, Ann. Neurol., 28, 561, 10.1002/ana.410280414 Mecocci, 1998, Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease?, Alzheimer Dis. Assoc. Disord., 12, 211, 10.1097/00002093-199809000-00015 Mayeux, 1999, Plasma amyloid beta-peptide 1–42 and incipient Alzheimer's disease, Ann. Neurol., 46, 412, 10.1002/1531-8249(199909)46:3<412::AID-ANA19>3.0.CO;2-A Mayeux, 2003, Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk, Neurology, 61, 1185, 10.1212/01.WNL.0000091890.32140.8F Mehta, 2001, Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease, Neurosci. Lett., 304, 102, 10.1016/S0304-3940(01)01754-2 Mehta, 2000, Plasma and cerebrospinal fluid levels of amyloid β proteins 1–40 and 1–42 in Alzheimer's disease, Arch. Neurol., 57, 100, 10.1001/archneur.57.1.100 Merched, 1998, Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry, FEBS Lett., 425, 225, 10.1016/S0014-5793(98)00234-8 Minoshima, 1997, Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease, Ann. Neurol., 42, 85, 10.1002/ana.410420114 Mintun, 2006, [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease, Neurology, 67, 446, 10.1212/01.wnl.0000228230.26044.a4 Molina, 1999, Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias, Neuroreport, 10, 3491, 10.1097/00001756-199911260-00005 Montaldi, 1990, Measurements of regional cerebral blood flow and cognitive performance in Alzheimer's disease, J. Neurol. Neurosurg. Psychiatry, 53, 33, 10.1136/jnnp.53.1.33 Montine, 1998, Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease, Ann. Neurol., 44, 410, 10.1002/ana.410440322 Montine, 1999, Increased CSF F2-isoprostane concentration in probable AD, Neurology, 52, 562, 10.1212/WNL.52.3.562 Montine, 1999, The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients, Am. J. Pathol., 155, 863, 10.1016/S0002-9440(10)65185-1 Montine, 2000, No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls, Ann. Neurol., 48, 950, 10.1002/1531-8249(200012)48:6<950::AID-ANA23>3.0.CO;2-F Montine, 2001, Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls, Arch. Pathol. Lab. Med., 125, 510, 10.5858/2001-125-0510-CFATAF Morgan, 2000, A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, 408, 982, 10.1038/35050116 Mori, 1995, Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau, Neurosci. Lett., 186, 181, 10.1016/0304-3940(95)11291-4 Morris, 2001, Pathologic correlates of nondemented aging, mild cognitive impairment, and early stage Alzheimer's disease, J. Mol. Neurosci., 17, 101, 10.1385/JMN:17:2:101 Mosconi, 2004, MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET, Neurology, 63, 2332, 10.1212/01.WNL.0000147469.18313.3B Motter, 1995, Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease, Ann. Neurol., 38, 643, 10.1002/ana.410380413 Moulin, 2007, Brain function during multi-trial learning in mild cognitive impairment: a PET activation study, Brain Res., 1136, 132, 10.1016/j.brainres.2006.12.021 Mulder, 2002, CSF markers related to pathogenetic mechanisms in Alzheimer's disease, J. Neural. Transm., 109, 1491, 10.1007/s00702-002-0763-y Munroe, 1995, Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease, Ann. Clin. Lab. Sci., 25, 207 Nestor, 2003, Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment, Ann. Neurol., 54, 343, 10.1002/ana.10669 Nielsen, 2007, Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies, Neurology, 69, 1569, 10.1212/01.wnl.0000271077.82508.a0 Nishimura, 1998, Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan, Methods Find Exp. Clin. Pharmacol., 20, 227, 10.1358/mf.1998.20.3.485673 Otto, 2000, Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease, Neurology, 54, 1099, 10.1212/WNL.54.5.1099 Palmert, 1990, Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease, Neurology, 40, 1028, 10.1212/WNL.40.7.1028 Pan, 2007, A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry, Proteomics, 7, 469, 10.1002/pmic.200600756 Perani, 1988, Technetium-99m HM-PAO-SPECT study of regional cerebral perfusion in early Alzheimer's disease, J. Nucl. Med., 29, 1507 Pesaresi, 2006, Plasma levels of beta-amyloid(1–42) in Alzheimer's disease and mild cognitive impairment, Neurobiol. Aging, 27, 904, 10.1016/j.neurobiolaging.2006.03.004 Petrella, 2006, Mild cognitive impairment: evaluation with 4-T functional MR imaging, Radiology, 240, 177, 10.1148/radiol.2401050739 Pike, 2007, Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease, Brain, 130, 2837, 10.1093/brain/awm238 Pirttila, 1994, Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease, Neurobiol. Aging, 15, 313, 10.1016/0197-4580(94)90026-4 Portelius, 2006, An Alzheimer's disease-specific B-amyloid fragment signature in cerebrospinal fluid, Neurosci. Lett., 409, 215, 10.1016/j.neulet.2006.09.044 Pratico, 1998, Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo, FASEB J., 12, 1777, 10.1096/fasebj.12.15.1777 Pratico, 2000, Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity, Ann. Neurol., 48, 809, 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9 Pratico, 2002, Increased brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer's disease, Arch. Neurol., 59, 972, 10.1001/archneur.59.6.972 Price, 2008, Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J, Cereb. Blood Flow Metab, 25, 1528, 10.1038/sj.jcbfm.9600146 Price, 1999, Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease, Ann. Neurol., 45, 358, 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X Price, 1991, The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease, Neurobiol. Aging, 12, 295, 10.1016/0197-4580(91)90006-6 Price, 2001, Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer's disease, Arch. Neurol., 58, 1395, 10.1001/archneur.58.9.1395 Prior, 1991, Quantitative changes in the amyloid beta A4 precursor protein in Alzheimer cerebrospinal fluid, Neurosci. Lett., 124, 69, 10.1016/0304-3940(91)90824-D Puchades, 2003, Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease, Mol. Brain Res., 118, 140, 10.1016/j.molbrainres.2003.08.005 Quinn, 2004, Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease, J. Alzheimers Dis., 6, 93, 10.3233/JAD-2004-6110 Rabinovici, 2007, 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration, Neurology, 68, 1205, 10.1212/01.wnl.0000259035.98480.ed Ray, 2007, Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins, Nat. Med., 13, 1359, 10.1038/nm1653 Riemenschneider, 2000, Cerebrospinal beta-amyloid ((1–42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline, Neurosci. Lett., 284, 85, 10.1016/S0304-3940(00)00976-9 Riemenschneider, 2002, Cerebrospinal fluid tau and B-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment, Arch. Neurol., 59, 1729, 10.1001/archneur.59.11.1729 Riemenschneider, 2002, Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration, Neurology, 58, 1622, 10.1212/WNL.58.11.1622 Ringman, 2008, Biochemical markers in persons with preclinical familial Alzheimer disease, Neurology, 71, 85, 10.1212/01.wnl.0000303973.71803.81 Rogers, 2001, Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease, Neurochem. Int., 39, 333, 10.1016/S0197-0186(01)00040-7 Roher, 1993, beta-Amyloid-(1–42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease, Proc. Natl. Acad. Sci. U. S. A., 90, 10836, 10.1073/pnas.90.22.10836 Roher, 1993, Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue, J. Neurochem., 61, 1916, 10.1111/j.1471-4159.1993.tb09834.x Rombouts, 2000, Functional MR imaging in Alzheimer's disease during memory encoding, AJNR Am. J. Neuroradiol., 21, 1869 Rosler, 1996, Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease, J. Neurol. Neurosurg. Psychiatry, 60, 237, 10.1136/jnnp.60.2.237-a Rosler, 2001, Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients, J. Neural. Transm., 108, 231, 10.1007/s007020170091 Rosler, 2001, Intra vitam lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukin-6 in Alzheimer's disease patients, Acta Neurol. Scand., 103, 126, 10.1034/j.1600-0404.2001.103002126.x Rowe, 2007, Imaging beta-amyloid burden in aging and dementia, Neurology, 68, 1718, 10.1212/01.wnl.0000261919.22630.ea Rowe, 2008, Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism, Lancet Neurol., 7, 129, 10.1016/S1474-4422(08)70001-2 Sakamoto, 2002, Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease, J. Neurol. Sci., 200, 27, 10.1016/S0022-510X(02)00114-4 Samuels, 1999, CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease, Neurology, 52, 547, 10.1212/WNL.52.3.547 Scheltens, 2002, Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion, Lancet Neurol., 1, 13, 10.1016/S1474-4422(02)00002-9 Schenk, 1999, Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse, Nature, 400, 173, 10.1038/22124 Scheuner, 1996, Secreted amyloid ß-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 APP mutations linked to familial Alzheimer's disease, Nature Med., 2, 852, 10.1038/nm0896-864 Schmitt, 2000, “Preclinical” AD revisited: neuropathology of cognitively normal older adults, Neurology, 55, 370, 10.1212/WNL.55.3.370 Schwarzman, 1996, Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation, Ciba Found Symp., 199, 146 Schwarzman, 1994, Transthyretin sequesters amyloid beta protein and prevents amyloid formation, Proc. Natl. Acad. Sci. U. S. A., 91, 8368, 10.1073/pnas.91.18.8368 Selle, 2005, Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease, Comb. Chem.High Throughput Screen, 8, 801, 10.2174/138620705774962391 Sennvik, 2000, Levels of alpha-and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients, Neurosci. Lett., 278, 169, 10.1016/S0304-3940(99)00929-5 Sheng, 1997, Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms, Acta Neuropathol., 94, 1, 10.1007/s004010050664 Shoghi-Jadid, 2002, Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease, Am. J. Geriatr. Psychiatry, 10, 24, 10.1097/00019442-200201000-00004 Shoji, 1991, Alpha 1-antichymotrypsin is present in diffuse senile plaques. A comparative study of beta-protein and alpha 1-antichymotrypsin immunostaining in the Alzheimer brain, Am. J. Pathol., 138, 247 Shoji, 1998, Combination assay of CSF tau, A beta 1–40 and A beta 1–42(43) as a biochemical marker of Alzheimer's disease, J. Neurol. Sci., 158, 134, 10.1016/S0022-510X(98)00122-1 Shoji, 2002, Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group, Neurobiol. Aging, 23, 363, 10.1016/S0197-4580(01)00309-8 Simonsen, 2007, Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment, Arch. Neurol., 64, 366, 10.1001/archneur.64.3.366 Sjogren, 2000, CSF levels of tau, beta-amyloid(1–42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging, J. Neural Transm., 107, 563, 10.1007/s007020070079 Sjogren, 2002, Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms, Dement. Geriatr. Cogn. Disord., 13, 112, 10.1159/000048642 Skoog, 1995, A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele, Neurodegeneration, 4, 433, 10.1006/neur.1995.0052 Skoog, 2003, Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds, Dement. Geriatr. Cogn. Disord., 15, 169, 10.1159/000068478 Small, 2006, PET of brain amyloid and tau in mild cognitive impairment, N. Engl. J. Med., 355, 2652, 10.1056/NEJMoa054625 Southwick, 1996, Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease, J. Neurochem., 66, 259, 10.1046/j.1471-4159.1996.66010259.x Sperling, 2003, fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease, J. Neurol. Neurosurg. Psychiatry, 74, 44, 10.1136/jnnp.74.1.44 Strozyk, 2003, CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study, Neurology, 60, 652, 10.1212/01.WNL.0000046581.81650.D0 Sunderland, 2003, Decreased beta-amyloid(1–42) and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease, JAMA, 289, 2094, 10.1001/jama.289.16.2094 Tamaoka, 1996, Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease, J. Neurol. Sci., 141, 65, 10.1016/0022-510X(96)00143-8 Tamaoka, 1997, Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease, J. Neurol. Sci, 1997, 41, 10.1016/S0022-510X(96)00314-0 Tapiola, 2008, MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study, Neurobiol. Aging, 29, 31, 10.1016/j.neurobiolaging.2006.09.007 Tarkowski, 1999, Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia, J. Clin. Immunol., 19, 223, 10.1023/A:1020568013953 Tato, 1995, Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type, J. Neurol. Neurosurg. Psychiatry, 59, 280, 10.1136/jnnp.59.3.280 Teunissen, 2002, Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid, Neurobiol. Aging, 23, 485, 10.1016/S0197-4580(01)00328-1 Thompson, 2003, Dynamics of gray matter loss in Alzheimer's disease, J. Neurosci., 23, 994, 10.1523/JNEUROSCI.23-03-00994.2003 Tsuzuki, 2000, Transthyretin binds amyloid beta peptides, Abeta1–42 and Abeta1–40 to form complex in the autopsied human kidney — possible role of transthyretin for abeta sequestration, Neurosci. Lett., 281, 171, 10.1016/S0304-3940(00)00834-X Tuppo, 2001, Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease, Brain Res. Bull., 54, 565, 10.1016/S0361-9230(01)00450-6 van Gool, 1995, Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease, Ann. Neurol., 37, 277, 10.1002/ana.410370221 Van Nostrand, 1992, Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients, Proc. Natl. Acad. Sci. U. S. A., 89, 2551, 10.1073/pnas.89.7.2551 van Oijen, 2006, Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case–cohort study, Lancet Neurol., 5, 655, 10.1016/S1474-4422(06)70501-4 Vandermeeren, 1993, Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbant assay, J. Neurochem., 61, 1828, 10.1111/j.1471-4159.1993.tb09823.x Vanderstichele, 2000, Standardization of measurement of β-amyloid(1–42) in cerebrospinal fluid and plasma, Int. J. Exp. Clin. Invest., 7, 245 Verhoeff, 2004, In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET, Am. J. Geriatr. Psychiatry, 12, 584 Versijpt, 2003, Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study, Eur. Neurol., 50, 39, 10.1159/000070857 Vigo-Pelfrey, 1995, Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease, Neurology, 45, 788, 10.1212/WNL.45.4.788 Wada-Isoe, 2004, Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients, Acta Neurol. Scand., 110, 124, 10.1111/j.1600-0404.2004.00286.x Weidemann, 1989, Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein, Cell, 57, 115, 10.1016/0092-8674(89)90177-3 West, 1993, Regionally specific loss of neurons in the aging human hippocampus, Neurobiol. Aging, 14, 287, 10.1016/0197-4580(93)90113-P West, 1994, Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease, Lancet, 344, 769, 10.1016/S0140-6736(94)92338-8 Whitwell, 2005, Comparisons between Alzheimer disease, frontotemporal lobar degeneration, and normal aging with brain mapping, Top. Magn. Reson. Imaging, 16, 409, 10.1097/01.rmr.0000245457.98029.e1 Whitwell, 2007, Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease, Brain, 130, 708, 10.1093/brain/awl388 Woodard, 1998, Compensatory recruitment of neural resources during overt rehearsal of word lists in Alzheimer's disease, Neuropsychology, 12, 491, 10.1037/0894-4105.12.4.491 Yamada, 1995, Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia, Neurosci. Lett., 186, 219, 10.1016/0304-3940(95)11318-Q Yao, 2003, Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia, Neurology, 61, 475, 10.1212/01.WNL.0000070185.02546.5D Zhang, 2004, Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetami de, for pet imaging of peripheral benzodiazepine receptor in primate brain, J. Med. Chem., 47, 2228, 10.1021/jm0304919 Zhang, 2005, Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer's disease, J. Alz. Dis., 7, 125, 10.3233/JAD-2005-7205 Zhang, 2005, Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease, J. Alz. Dis., 7, 125, 10.3233/JAD-2005-7205 Zougman, 2008, Integrated analysis of the cerebrospinal fluid peptidome and proteome, J. Proteome Res., 7, 386, 10.1021/pr070501k